HC Wainwright upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a report issued on Thursday morning, Zacks.com reports.
Bradmer Pharmaceuticals Price Performance
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported C($0.55) EPS for the quarter.
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- Differences Between Momentum Investing and Long Term Investing
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.